Cargando…

Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a multicomponent condition that is characterised by airflow obstruction that is not fully reversible and is a major global cause of morbidity and mortality. The most widely used marker of disease severity and progression is FEV(1). However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duvoix, Annelyse, Dickens, Jenny, Haq, Imran, Mannino, David, Miller, Bruce, Tal-Singer, Ruth, Lomas, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711372/ https://www.ncbi.nlm.nih.gov/pubmed/22744884 http://dx.doi.org/10.1136/thoraxjnl-2012-201871

Ejemplares similares

Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts
por: Valvi, Deepa, et al.
Publicado: (2012)

COPD association and repeatability of blood biomarkers in the ECLIPSE cohort
por: Dickens, Jennifer A, et al.
Publicado: (2011)

The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial
por: Fisk, Marie, et al.
Publicado: (2018)

Fibrinogen: A Feasible Biomarker in Identifying the Severity and Acute Exacerbation of Chronic Obstructive Pulmonary Disease
por: Mohan, Mikash, et al.
Publicado: (2021)

Fibrinogen is a promising biomarker for chronic obstructive pulmonary disease: evidence from a meta-analysis
por: Zhou, Bo, et al.
Publicado: (2020)

Integrated analysis reveals lung fibrinogen gamma chain as a biomarker for chronic obstructive pulmonary disease
por: Zhang, Hai, et al.
Publicado: (2021)

The genetics of chronic obstructive pulmonary disease
por: Lomas, David A, et al.
Publicado: (2001)

Update on the management of chronic obstructive pulmonary disease
por: Maas, Andrea K, et al.
Publicado: (2010)

Is It Time to Abandon the Postbronchodilator Requirement in Defining Chronic Obstructive Pulmonary Disease?
por: Mannino, David M.
Publicado: (2022)

Is One Exacerbation Enough to Modify Therapy in Chronic Obstructive Pulmonary Disease?
por: Mannino, David M.
Publicado: (2023)

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial
por: Lazaar, Aili L., et al.
Publicado: (2020)

Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease
por: Singh, Dave, et al.
Publicado: (2020)

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
por: Singh, Dave, et al.
Publicado: (2021)

Genetics of Sputum Gene Expression in Chronic Obstructive Pulmonary Disease
por: Qiu, Weiliang, et al.
Publicado: (2011)

Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey
por: Mannino, David, et al.
Publicado: (2022)

Defining and targeting health disparities in chronic obstructive pulmonary disease
por: Pleasants, Roy A, et al.
Publicado: (2016)

Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes
por: Aryal, Shambhu, et al.
Publicado: (2014)

Circulating testosterone levels and health outcomes in chronic obstructive pulmonary disease: results from ECLIPSE and ERICA
por: Pavey, Holly, et al.
Publicado: (2023)

Biomarkers of collagen turnover are related to annual change in FEV(1) in patients with chronic obstructive pulmonary disease within the ECLIPSE study
por: Leeming, Diana J., et al.
Publicado: (2017)

Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease
por: Kelly, Emer, et al.
Publicado: (2013)

Altered native stability is the dominant basis for susceptibility of α(1)-antitrypsin mutants to polymerization
por: Irving, James A., et al.
Publicado: (2014)

Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort
por: Rønnow, Sarah Rank, et al.
Publicado: (2019)

Blood eosinophils in chronic obstructive pulmonary disease: A potential biomarker
por: Cui, Yanan, et al.
Publicado: (2023)

Fibrinogen, Fibrinogen-like 1 and Fibrinogen-like 2 Proteins, and Their Effects
por: Sulimai, Nurul H., et al.
Publicado: (2022)

Variants in FAM13A are associated with chronic obstructive pulmonary disease
por: Cho, Michael H., et al.
Publicado: (2010)

Association Between Routine Blood Biomarkers and Clinical Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Disease
por: Nuñez, Alexa, et al.
Publicado: (2020)

Health-related quality of life and chronic obstructive pulmonary disease in North Carolina
por: Brown, David W., et al.
Publicado: (2010)

Trends in the Use, Sociodemographic Correlates, and Undertreatment of Prescription Medications for Chronic Obstructive Pulmonary Disease among Adults with Chronic Obstructive Pulmonary Disease in the United States from 1999 to 2010
por: Ford, Earl S., et al.
Publicado: (2014)

Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease
por: Wu, Benjamin, et al.
Publicado: (2022)

A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease
por: Menche, Jörg, et al.
Publicado: (2014)

Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease
por: Lock-Johansson, Sofie, et al.
Publicado: (2014)

Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study
por: O’Neal, Wanda K, et al.
Publicado: (2014)

Gastrointestinal stromal tumors: Fibrinogen levels are associated with prognosis of patients as blood-based biomarker
por: Lu, Jing, et al.
Publicado: (2018)

The Influence of Radiographic Phenotype and Smoking Status on Peripheral Blood Biomarker Patterns in Chronic Obstructive Pulmonary Disease
por: Bon, Jessica M., et al.
Publicado: (2009)

Cardiac biomarkers of prognostic importance in chronic obstructive pulmonary disease
por: Nilsson, Ulf, et al.
Publicado: (2020)

Reactive centre loop mutants of α-1-antitrypsin reveal position-specific effects on intermediate formation along the polymerization pathway
por: Haq, Imran, et al.
Publicado: (2013)

Reactive centre loop mutants of α-1-antitrypsin reveal position-specific effects on intermediate formation along the polymerization pathway
por: Haq, Imran, et al.
Publicado: (2013)

Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD)
por: Globe, Gary, et al.
Publicado: (2016)

Gamma' Fibrinogen Levels As a Biomarker of COVID-19 Severity
por: Kornblith, Lucy Z, et al.
Publicado: (2022)

Life expectancy and years of life lost in chronic obstructive pulmonary disease: Findings from the NHANES III Follow-up Study
por: Shavelle, Robert M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_rmdfk6kns0qha8mcrn0skp77i4